International journal of cardiology · 2025
Echocardiographic grading of right ventricular dysfunction improves risk stratification of patients with severe heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Astengo Marco, Lindow Thomas, Bobbio Emanuele, Bollano Entela, Dellgren Göran, Bech-Hanssen Odd
Аннотация
BACKGROUND: Right ventricular dysfunction (RVD) is a marker of adverse outcomes in heart failure (HF). We used a 5-point RVD score to describe three phenotypes (preserved RV function, RVD and RV failure) and investigated their relationhip with cardiac function and their contribution to risk stratification.
METHODS: Patients (n = 201) with HF, undergoing right heart catheterization and echocardiography were included. The RVD score comprised pulmonary hypertension, reduced tricuspid annular plane systolic excursion (TAPSE), RV enlargement, ≥ moderate tricuspid regurgitation and decreased vena cava inferior collapsibility. The endpoint was a composite of all-cause mortality or left ventricular (LV) assist device implantation.
RESULTS: Mean age was 52 ± 14 years, LV ejection fraction was 24 ± 8 %. Patients with RVD3-5 (n = 93) had, compared with RVD1-2 (n = 81) and RVD0 (n = 27), more deformed RV with higher RVdiameter/RVlenght ratio (P < 0.001) and higher RV end-diastolic pressure (P < 0.001). Among patients with RVD0, 77 % had compensated HF, while 65 % of RVD3-5 had overt HF. During 17 months of follow-up, 64 patients met the endpoint. There was an increase in adverse events from RVD0 to RVD1-2 and RVD3-5 (0, 25 and 47 %, P < 0.001). At univariable analysis, TAPSE, TAPSE/systolic pulmonary pressure and the RVD score were associated with the risk of adverse outcomes. After adjusting for clinical and echocardiographic characteristics, only the RVD score remained associated with the endpoint (HR 1.97, 95 % CI 1.08-3.70, P = 0.03).
CONCLUSIONS: Increments of the RVD score reflect worsening of RV and LV function and improve risk stratification of patients with severe HF.
METHODS: Patients (n = 201) with HF, undergoing right heart catheterization and echocardiography were included. The RVD score comprised pulmonary hypertension, reduced tricuspid annular plane systolic excursion (TAPSE), RV enlargement, ≥ moderate tricuspid regurgitation and decreased vena cava inferior collapsibility. The endpoint was a composite of all-cause mortality or left ventricular (LV) assist device implantation.
RESULTS: Mean age was 52 ± 14 years, LV ejection fraction was 24 ± 8 %. Patients with RVD3-5 (n = 93) had, compared with RVD1-2 (n = 81) and RVD0 (n = 27), more deformed RV with higher RVdiameter/RVlenght ratio (P < 0.001) and higher RV end-diastolic pressure (P < 0.001). Among patients with RVD0, 77 % had compensated HF, while 65 % of RVD3-5 had overt HF. During 17 months of follow-up, 64 patients met the endpoint. There was an increase in adverse events from RVD0 to RVD1-2 and RVD3-5 (0, 25 and 47 %, P < 0.001). At univariable analysis, TAPSE, TAPSE/systolic pulmonary pressure and the RVD score were associated with the risk of adverse outcomes. After adjusting for clinical and echocardiographic characteristics, only the RVD score remained associated with the endpoint (HR 1.97, 95 % CI 1.08-3.70, P = 0.03).
CONCLUSIONS: Increments of the RVD score reflect worsening of RV and LV function and improve risk stratification of patients with severe HF.